Home Featured Page 195

Featured

Latest

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Weekly Psychedelic Policy Briefing: August 23, 2026

Numinus to Acquire Novamind, Creating the North American Industry Leader in...

PT308 – Dr. Ido Cohen, PsyD – Vital Psychedelic Conversations

Psychedelic Bulletin: Homecoming Raises $4m Seed; Angermayer Increases atai Stake by...

Entheon Biomedical Announces Non-Brokered Private Placement Financing

Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule...

MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1...

PT307 – Kathryn L. Tucker, JD – The Right to Try...

Health Canada Approves First Special Access Program Requests for Psilocybin

Psychedelic Bulletin: Bizarre News from Across the Psychedelics Space (April 1,...

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

Weekly Psychedelic Policy Briefing: August 23, 2026

Numinus to Acquire Novamind, Creating the North American Industry Leader in...

PT308 – Dr. Ido Cohen, PsyD – Vital Psychedelic Conversations

Psychedelic Bulletin: Homecoming Raises $4m Seed; Angermayer Increases atai Stake by...

Entheon Biomedical Announces Non-Brokered Private Placement Financing

Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule...

MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1...

PT307 – Kathryn L. Tucker, JD – The Right to Try...

Health Canada Approves First Special Access Program Requests for Psilocybin

Psychedelic Bulletin: Bizarre News from Across the Psychedelics Space (April 1,...

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY